Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center


Clamping Down the Metabolic Pipeline to B Cells

Submitted by robbikm2 on

New research shows the nutritive needs of B cells are more flexible than previously thought, which could enable researchers to steer antibody production in the lymph nodes and spleen to better combat autoimmunity. Patients with high-risk diseases of the immune system, particularly systemic lupus erythematosus, could stand to benefit from the research findings. The study led by Mark Boothby, MD, and published in the Journal of Immunology, provides details regarding how murine B cells use different sugars as they mature into antibody-producing cells

https://discoveries.vanderbilthealth.com/2024/02/clamping-down-the-metabolic-pipeline-to-b-cells/
Vanderbilt Health
Locked

Please s

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Submitted by robbikm2 on

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/
Tom Wilemon
Locked


A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Multiple Cancer Types

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select
solid tumors who meet study enrollment criteria. The main questions it aims to answer are:

1. what is the maximum tolerated dose and recommended dose for phase 2?

2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or
twice per day?
Breast, Cervical, Gastrointestinal, Gynecologic, Head/Neck, Lung, Phase I, Urologic
I
Berlin, Jordan
NCT05683418
VICC-DTPHI23103

Phase 1b Combo w/ Ribociclib and Alpelisib

Multiple Cancer Types

This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are
as follows:

Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI, Novartis Pharmaceuticals
Corporation).

Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY, Novartis Pharmaceuticals
Corporation).
Breast, Phase I
I
Abramson, Vandana
NCT05508906
VICCBREP2267

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.